Skip to content
Menu

Metagenomi Therapeutics, Inc. MGX

Full chart Compare
Set alert

Price alert · MGX

All alert types
0.61 USD -0.02 (-3.45%)

As ofNov 19, 2026, 3:49 PM EST

0.61 Day range 0.6423
0.60 52-week range 1.87
YTD
-62.35%
1 year
-62.11%

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 18.40 +2916.4% upside
Target (low)
14.00
Target (mean)
18.40
Target (high)
25.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy4
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 6
  • 1 month ago 7
  • 2 months ago 7
  • 3 months ago 7

Included in Essentials and up

Sign in to see Revenue and earnings forecast

Reported revenue and earnings per share by year, then what analysts expect next.

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

MGX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.58333-0.66 – -0.45-9.91+94.1%9.46M-23.7%3
Next quarter-0.69-0.71 – -0.67-2.08+66.8%6.25M-44.0%2
Current year-2.48-2.84 – -2.17-36.49+93.2%51.63M+15.3%4
Next year-2.88-3.26 – -2.60-2.48-16.0%33.16M-35.8%4

Upgrades and downgrades

The latest rating changes

MGX analyst upgrades and downgrades
DateFirmActionFromTo
Dec 10, 2024HC Wainwright & Co.MaintainedBuyBuy
Nov 21, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 20, 2024Chardan CapitalMaintainedBuyBuy
Oct 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 6, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 5, 2024Chardan CapitalMaintainedBuyBuy
Aug 21, 2024HC Wainwright & Co.MaintainedBuyBuy
Aug 19, 2024Chardan CapitalMaintainedBuyBuy
Aug 15, 2024BMO CapitalMaintainedOutperformOutperform
Jul 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 7, 2024HC Wainwright & Co.Initiated—Buy
May 2, 2024JP MorganDowngradeOverweightNeutral
Mar 28, 2024Chardan CapitalMaintainedBuyBuy
Mar 5, 2024TD CowenInitiated—Outperform
Mar 5, 2024Wells FargoInitiated—Overweight
Mar 5, 2024JP MorganInitiated—Overweight
Mar 5, 2024JefferiesInitiated—Buy
Mar 5, 2024BMO CapitalInitiated—Outperform
Mar 5, 2024Chardan CapitalInitiated—Buy

Included in Plus and up

Sign in to see Analyst trend

Two years of the analyst rating mix and the average price target against the price.